Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 4:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,050 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Cancer, Quality of Life
Interventions
amifostine trihydrate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer, Complex Atypical Endometrial Hyperplasia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Early Menopause, Menopause
Interventions
Nitrate supplementation, placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, oglufanide disodium, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Cytran
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Glendale, California • Los Gatos, California • Stanford, California + 15 more
Conditions
Ovarian Cancer
Interventions
Gleolan
Drug
Lead sponsor
NX Development Corp
Industry
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Neoplasms
Interventions
taxol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

S9912 Combination Chemo in Stage III Ovarian Cancer,

NCT00003896
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
cisplatin, liposomal doxorubicin, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
104
States / cities
Tucson, Arizona • Davis, California • Duarte, California + 66 more
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

NCT04684602
Conditions
Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
Interventions
PrimePro™/ PrimeMSK™
Biological
Lead sponsor
Thomas Advanced Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Culver City, California
Conditions
Solid Tumor
Interventions
CPO-100
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more
Conditions
Platinum-resistant Ovarian Cancer
Interventions
MEN2501
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Springdale, Arkansas • New Haven, Connecticut • Sarasota, Florida + 4 more
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Carboplatin, Pembrolizumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions
BCA101, Pembrolizumab
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
Conditions
Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic, Non-small Cell Lung Cancer (NSCLC)
Interventions
CR-002
Drug
Lead sponsor
Crescent Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Austin, Texas • Dallas, Texas • Fairfax, Virginia
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Interventions
Web based survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
Conditions
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions
Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
Device · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Ovarian Cancer, Merkel Cell Carcinoma, SCLC
Interventions
BB-10901
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
6
States / cities
San Francisco, California • Las Vegas, Nevada • Columbus, Ohio + 3 more
Conditions
Ovarian Cancer
Interventions
Drug Response Predictor® (DRP)
Device
Lead sponsor
Allarity Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Albuquerque, New Mexico + 4 more